Supporting Information

A Lutidine-Promoted Photoredox Catalytic Atom-Transfer Radical Cyclization Reaction for the Synthesis of 4-Bromo-3,3-dialkyl-octahydro-indol-2-ones

Quan-Sheng Zhao,^{a,b} Guo-Qiang Xu,^a Ji-Tao Xu,^a Zhu-Yin Wang,^a and Peng-Fei Xu^{* a}

 ^a State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, P. R. China
 ^b Key Laboratory of Functional Molecular Solids, Ministry of Education; Anhui Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu 241002, P. R. China

E-mail: xupf@lzu.edu.cn

Contents

1. General information	3
2. Optimization of the reaction conditions	4
3. Preparation of substrates	6
3.1 List of substrates	6
3.2 General procedure for the synthesis of substrates	8
4. General procedure for the photocatalytic ATRC reactions	9
4.1 General procedure for the synthesis of compounds 3	9
4.2 Procedure for scale-up preparation of 3aa	9
5. Characterization of products	10
6. X-Ray crystallographic data	22
6.1 X-Ray Crystallographic Data of Product 3aa	22
6.2 X-Ray Crystallographic Data of product 3an	23
7. Mechanistic studies	24
7.1 Radical trapping experiments	24
7.2 Stern-Volmer fluorescence quenching experiments	26
8. NMR spectra of products	28

1. General information

All glassware was thoroughly oven-dried. Chemicals and solvents were either purchased from commercial suppliers or purified by standard techniques. Thin-layer chromatography (TLC) plates were visualized by exposure to ultraviolet light and/or staining with phosphomolybdic acid followed by heating on a hot plate. Flash chromatography was carried out using silica gel (200-300 mesh). ¹H NMR and ¹³C NMR spectra were recorded on a Bruker AM-400 (400 MHz). The spectra were recorded in deuterochloroform (CDCl₃) as solvent at room temperature, ¹H and ¹³C NMR chemical shifts are reported in ppm relative to the residual solvent peak. The residual solvent signals were used as references and the chemical shifts were converted to the TMS scale (CDCl₃: $\delta_{\rm H} = 0$ ppm, $\delta_{\rm C} = 77.00$ ppm). Data for ¹H NMR are reported as follows: chemical shift (δ ppm), mul-tiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet), integration, coupling constant (Hz) and assignment. Data for ¹³C NMR are reported as chemical shift. HRMS were performed on a Bruker Apex II mass instrument (ESI).

2. Optimization of the reaction conditions

Table 51, bereening of 1 notocatarysts, Dases, and borvents	Table	S1 .	Screen	ing of	Photoca	talysts,	Bases,	and	Solvents ^{<i>a</i>}
---	-------	-------------	--------	--------	---------	----------	--------	-----	-------------------------------------

<	0 N 1a (0.1 m	Me + Br - Phi mmol) 2a (1 equiv)	otocatalyst (X mol %) Base, Solvent rt.; Blue LEDs; 24 h	OMe Br 3aa	
Entry	1a:2a	Photocatalyst (X mol%)	Base (Y equiv)	Solvent	Yield (%) ^b
1	1:1	<i>fac</i> -Ir(ppy) ₃	2,6-lutidine	MeCN	57
2	1:1	$Ir[dF(CF_3)ppy]_2(dtbbpy)PF_6$	2,6-lutidine	MeCN	55
3	1:1	Ir(ppy) ₂ (dtbbpy)PF ₆	2,6-lutidine	MeCN	50
4	1:1	Ru(bpy) ₃ Cl ₂	2,6-lutidine	MeCN	36
5 ^{<i>c</i>}	1:1	Eosin Y	2,6-lutidine	MeCN	NR^d
6	1:1	AcrMesClO ₄	2,6-lutidine	MeCN	NR
7	1:1	-	2,6-lutidine	MeCN	NR
8 ^e	1:1	<i>fac</i> -Ir(ppy) ₃	2,6-lutidine	MeCN	NR
9	1:1	<i>fac</i> -Ir(ppy) ₃	-	MeCN	24
10	1:1	<i>fac</i> -Ir(ppy) ₃ (Open air)	2,6-lutidine	MeCN	trace
11	1:1	<i>fac</i> -Ir(ppy) ₃	Na ₂ HPO ₄	MeCN	50
12	1:1	<i>fac</i> -Ir(ppy) ₃	K ₂ CO ₃	MeCN	36
13	1:1	<i>fac</i> -Ir(ppy) ₃	DIPEA	MeCN	33
14	1:1	<i>fac</i> -Ir(ppy) ₃	Et ₃ N	MeCN	37
15	1:1	<i>fac</i> -Ir(ppy) ₃	2,6-lutidine	toluene	68
16	1:1	<i>fac</i> -Ir(ppy) ₃	2,6-lutidine	DCM	60
17	1:1	<i>fac</i> -Ir(ppy) ₃	2,6-lutidine	THF	70
18	1:1	<i>fac</i> -Ir(ppy) ₃	2,6-lutidine	1,4-dioxane	56
19	1:1	<i>fac</i> -Ir(ppy) ₃	2,6-lutidine	DMSO	trace
20	1:1	<i>fac</i> -Ir(ppy) ₃	2,6-lutidine	Mesitylene	67
21	1:1	<i>fac</i> -Ir(ppy) ₃	2,6-lutidine	Et ₂ O	41

22 ^f	1:1	<i>fac</i> -lr(ppy) ₃	2,6-lutidine(0.5)	toluene	75
23 ^{fg}	1:1.2	<i>fac</i> -Ir(ppy) ₃	2,6-lutidine(0.5)	toluene	81
24	1:1.5	<i>fac</i> -Ir(ppy) ₃	2,6-lutidine(0.5)	toluene	81
25	1:1.2	<i>fac</i> -Ir(ppy) ₃ / 0.5	2,6-lutidine(0.5)	toluene	64
26 ^{fgh}	1:1.2	<i>fac</i> -Ir(ppy) ₃ / 2	2,6-lutidine(0.5)	toluene	82
27	1:1.2	fac-Ir(ppy) ₃ / 2	2,6-lutidine(0.5)	toluene(0.5 mL)	70
28 ^{fhi}	1:1.2	<i>fac</i> -Ir(ppy) ₃	2,6-lutidine(0.5)	toluene (2 mL)	85

^{*a*}Reaction conditions: **1a** (0.1 mmol), **2a** (1.0 equiv), photocatalyst (1 mol%), base (1.0 equiv), solvent (1 mL), and blue LEDs under N₂ at room temperature for 24 h. ^{*b*}Isolated yield. ^{*c*}Green LEDs. ^{*d*}NR (No Reaction). ^{*e*}No light. ^{*f*}Base (0.5 equiv). ^{*g*}2a (1.2 equiv). ^{*b*}photocatalyst (2 mol%). ^{*i*}solvent (2 mL).

Table S2. Screening of Amounts of Pyridine



Entry	Base (0.5 equiv)	Yield
1	2,6-lutidine	85
2	pyridine	29
3	2,6-di <i>t</i> Bu-Py	68
4	2,6-ditBu-4-Me-Py	65
5	2,4,6-Collidine	80
6	2,6-diCl-Py	41
7	Pentafluoropyridine	30
8	4-Dimethylaminopyridine (DMAP)	trace
9	4-Pyrrolidinopyridine	trace
10	2-NH ₂ -Py	NR
11	2,6-lutidine (0.5 equiv) + PyHBr (0.5 equiv)	78
12	2,6-lutidine (0.25 equiv)	56
13	2,6-lutidine (0.10 equiv)	35

3. Preparation of substrates

3.1 List of substrates







3.2 General procedure for the synthesis of substrates



Preparation of S1

According to a modified literature procedure,¹ under an air atmosphere, cyclohexene (10.1 mL, 100 mmol, 1.0 equiv) was added to a 150 mL round bottom flask containing a suspension of AIBN (12.5 mg, cat.) and NBS (11.572 g, 65 mmol, 0.65 equiv) in cyclohexane (50 mL); the round bottom was fitted with a condenser, and refluxed at 80 °C for 3 hours. The reaction was cooled to room temperature, filtered through a glass frit, and carefully concentrated *in vacuo* to yield a crude oil. Vacuum distillation yielded **S1** (8.35 g, 80% with respect to NBS) as a colorless oil. The material was used within one day of preparation, or stored at -20 °C indefinitely.

Preparation of S2-a

According to a modified literature procedure,² a solution of aniline (3.2 mL, 35 mmol, 2.7 equiv) in MeCN (40 mL) was treated with 3-bromocyclohexene **S1** (1.50 mL, 13.0 mmol, 1.0 equiv) and K₂CO₃ (1.97 g, 14.3 mmol, 1.1 equiv). After 2 h at rt, the reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed with brine (30 mL), dried over Na₂SO₄, filtered, evaporated under reduced pressure and purified by column chromatography (PE/EA = 50:1–30:1) to give amine **S2-a** (2.137 g, 95 %) as a colourless oil.

Preparation of 1

According to a modified literature procedure,³ methacryloyl chloride (2 equiv) in toluene (0.13 M) was added on a mixture of amine **S2** (1 equiv), triethylamine (2 equiv) and DMAP (0.1 equiv) in toluene (0.13 M). The mixture was stirred overnight at reflux. The reaction was quenched with saturated aqueous Na₂CO₃ (15 mL), then the mixture was extracted with dichloromethane (3 x 15 mL). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (PE/EA = 6:1–4:1) affording the corresponding substrate **1**.

References

(1) Shuler, S. A.; Yin, G.; Krause, S. B.; Vesper, C. M.; Watson, D. A. Synthesis of Secondary Unsaturated Lactams via an Aza-Heck Reaction. *J. Am. Chem. Soc.* 2016, *138*, 13830–13833.
 (2) Grainger, R. S.; Betou, M.; Male, L.; Pitak, M. B.; Coles, S. J. Semipinacol Rearrangement of Cis-Fused β-Lactam Diols into Keto-Bridged Bicyclic Lactams. *Org. Lett.* 2012, *14*, 2243–2237.
 (3) Kong, W.; Casimiro, M.; Fuentes, N.; Merino, E.; Nevado, C. Metal-Free Aryltrifluoromethylation of Activated Alkenes. *Angew. Chem., Int. Ed.* 2013, *52*, 13086–13090.

4. General procedure for the photocatalytic ATRC reactions

4.1 General procedure for the synthesis of compounds 3



2-Bromo(Chloro)acetophenone 2 (0.12 mmol, 1.2 equiv) and 2,6-lutidine (0.05 mmol, 0.5 equiv) were added to a solution of substrate 1 (0.1 mmol, 1 equiv) and photocatalyst *fac*-Ir(ppy)₃ (1 mol%) in dry toluene (2 mL) at room temperature. The mixture was degassed by three cycles of freeze-pump-thaw and then placed in the irradiation apparatus equipped with a 3 W blue light-emitting diodes (LEDs) strip. The resulting mixture was stirred at room temperature for 24 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, and the resulting crude mixture was purified by flash column chromatography on silica gel (PE/EA = 6:1–2:1) to afford the desired product **3**.

4.2 Procedure for scale-up preparation of 3aa



2-Bromoacetophenone **2a** (6 mmol, 1.19 g, 1.2 equiv) and 2,6-lutidine (2.5 mmol, 0.6 mL, 0.5 equiv) were added to a solution of substrate **1a** (5 mmol, 1.21 g, 1 equiv) and photocatalyst *fac*-Ir(ppy)₃ (32.5 mg, 1 mol%) in dry toluene (50 mL) at room temperature. The mixture was degassed by three cycles of freeze-pump-thaw and then placed in the irradiation apparatus equipped with a 3 W blue LEDs strip. The resulting mixture was stirred at room temperature for 48 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, and the resulting crude mixture was purified by flash column chromatography on silica gel (PE/EA = 4:1) to afford the desired product **3aa** (yield 73%, 1.60 g).

5. Characterization of products



4-Bromo-3-methyl-3-(3-oxo-3-phenylpropyl)-1-phenyloctahydro-2H-indol-2-one (3aa) Purification by flash column chromatography (SiO₂, PE/EA = 4:1) afforded **3aa**.

White solid, 37.3 mg, 85% yield, mp = 156-158 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.96 (d, J = 7.4 Hz, 2H), 7.54 (t, J = 7.3 Hz, 1H), 7.49–7.35 (m, 6H), 7.24–7.21 (m, 1H), 4.63–4.38 (m, 2H), 3.18–3.07 (m, 2H), 2.87 (dd, J = 7.1, 5.0 Hz, 1H), 2.24–2.02 (m, 4H), 1.96–1.92 (m, 1H), 1.79–1.68 (m, 1H), 1.64–1.52 (m, 2H), 1.43 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ199.60, 176.84 137.20, 136.69, 133.05, 129.11, 128.55, 128.15, 126.11, 124.03, 55.70, 50.22, 48.38, 47.90, 34.23, 33.68, 31.69, 27.16, 20.72, 18.88.

HRMS (ESI) for $C_{24}H_{27}BrNO_2 [M+H]^+$ calcd. 440.1220, found 440.1221.



4-Bromo-1-(4-fluorophenyl)-3-methyl-3-(3-oxo-3-phenylpropyl)octahydro-2H-indol-2-one (3ba)

Purification by flash column chromatography (SiO₂, PE/EA = 3:1) afforded **3ba**.

Yellow solid, 29.2 mg, 64% yield, mp = 120-122 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.96 (d, J = 7.3 Hz, 2H), 7.54 (t, J = 7.4 Hz, 1H), 7.43 (t, J = 7.6 Hz, 2H), 7.39–7.33 (m, 2H), 7.08 (t, J = 8.6 Hz, 2H), 4.49 (dd, J = 11.3, 4.7 Hz, 1H), 4.43 (dd, J = 12.8, 7.6 Hz, 1H), 3.22–3.01 (m, 2H), 2.86 (dd, J = 7.0, 5.2 Hz, 1H), 2.19–2.03 (m, 4H), 1.94–1.87 (m, 1H), 1.73–1.70 (m, 1H), 1.60–1.49 (m, 2H), 1.42 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 199.41, 176.91, 160.48 (d, *J* = 247.5 Hz), 136.59, 133.01, 128.49, 128.04, 126.02, 125.93, 115.99, 115.77, 55.91, 50.04, 48.46, 47.68, 34.23, 33.51, 31.50, 26.98, 20.50, 18.81.

HRMS (ESI) for $C_{24}H_{26}BrFNO_2$ [M+H]⁺ calcd. 458.1125, found 458.1124.



4-Bromo-1-(4-chlorophenyl)-3-methyl-3-(3-oxo-3-phenylpropyl)octahydro-2H-indol-2-one (3ca)

Purification by flash column chromatography (SiO₂, PE/EA = 4:1) afforded **3ca**.

Yellow solid, 33.1 mg, 70% yield, mp = 154-156 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.95 (d, J = 7.5 Hz, 2H), 7.54 (t, J = 7.2 Hz, 1H), 7.45–7.35 (m, 6H), 4.49 (d, J = 9.6 Hz, 2H), 3.27–2.96 (m, 2H), 2.86 (d, J = 5.2 Hz, 1H), 2.22–2.03 (m, 4H), 1.96–1.91 (m, 1H), 1.75–1.70 (m, 1H), 1.55–1.50 (m, 2H), 1.41 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 199.32, 176.83, 136.55, 135.67, 133.01, 131.19, 129.13, 128.48, 128.03, 124.97, 55.46, 49.97, 48.19, 47.79, 34.03, 33.53, 31.57, 26.96, 20.71, 18.74.

HRMS (ESI) for $C_{24}H_{26}BrCINO_2 [M+H]^+$ calcd. 474.0830, found 474.0833.



4-Bromo-1-(4-bromophenyl)-3-methyl-3-(3-oxo-3-phenylpropyl)octahydro-2H-indol-2-one (3da)

Purification by flash column chromatography (SiO₂, PE/EA = 4:1) afforded **3da**.

White solid, 37.7 mg, 73% yield, mp = 162-164 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 7.99–7.92 (m, 2H), 7.57–7.49 (m, 3H), 7.46–7.41 (m, 2H), 7.37–7.32 (m, 2H), 4.60–4.39 (m, 2H), 3.14–3.07 (m, 2H), 2.85 (dd, J = 7.2, 4.8 Hz, 1H), 2.15–2.07 (m, 4H), 2.01–1.91 (m, 1H), 1.76–1.72 (m, 1H), 1.61–1.49 (m, 2H), 1.41 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 199.37, 176.84, 136.62, 136.27, 133.06, 132.11, 128.52, 128.07, 125.22, 119.06, 55.40, 49.94, 48.21, 47.87, 34.05, 33.54, 31.62, 26.99, 20.70, 18.76.

HRMS (ESI) for $C_{24}H_{26}Br_2NO_2 [M+H]^+$ calcd. 518.0325, found 518.0324.



4-Bromo-1-(4-iodophenyl)-3-methyl-3-(3-oxo-3-phenylpropyl)octahydro-2H-indol-2-one (3ea)

Purification by flash column chromatography (SiO₂, PE/EA = 3:1) afforded **3ea**.

White solid, 36.7 mg, 65% yield, mp = 136-138 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.99–7.91 (m, 2H), 7.75–7.66 (m, 2H), 7.53 (dd, J = 10.5, 4.3 Hz, 1H), 7.43 (t, J = 7.6 Hz, 2H), 7.26–7.19 (m, 2H), 4.53–4.51 (m, 2H), 3.25–2.96 (m, 2H), 2.85 (dd, J = 7.2, 4.8 Hz, 1H), 2.21–2.03 (m, 4H), 2.00–1.89 (m, 1H), 1.78–1.67 (m, 1H), 1.59–1.48 (m, 2H), 1.41 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 199.31, 176.77, 138.03, 136.98, 136.59, 133.02, 128.49, 128.04, 125.35, 90.05, 55.24, 49.94, 48.12, 47.87, 34.00, 33.52, 31.61, 26.95, 20.70, 18.73.

HRMS (ESI) for $C_{24}H_{26}BrINO_2 [M+H]^+$ calcd. 566.0186, found 566.0185.



4-Bromo-3-methyl-3-(3-oxo-3-phenylpropyl)-1-(p-tolyl)octahydro-2H-indol-2-one (3fa) Purification by flash column chromatography (SiO₂, PE/EA = 5:1) afforded **3fa**. Yellow oil, 35.3 mg, 78% yield.

¹**H** NMR (400 MHz , CDCl₃) δ 7.99–7.92 (m, 2H), 7.54–7.50 (m, 1H), 7.42 (t, *J* = 7.6 Hz, 2H), 7.27 (d, *J* = 8.3 Hz, 2H), 7.19 (d, *J* = 8.2 Hz, 2H), 4.51–4.47 (m, 1H), 4.45–4.40 (m, 1H), 3.20–3.03 (m, 2H), 2.85 (dd, *J* = 7.1, 5.2 Hz, 1H), 2.33 (s, 3H), 2.18–2.00 (m, 4H), 1.94–1.85 (m, 1H), 1.72–1.66 (m, 1H), 1.61–1.48 (m, 2H), 1.41 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ199.46, 176.65, 136.55, 135.83, 134.41, 132.90, 129.56, 128.41, 128.00, 123.98, 55.68, 50.25, 48.36, 47.67, 34.22, 33.56, 31.53, 26.94, 20.86, 20.47, 18.81. HRMS (ESI) for C₂₅H₂₉BrNO₂ [M+H]⁺ calcd. 454.1376, found 454.1374.



4-Bromo-1-(4-(tert-butyl)phenyl)-3-methyl-3-(3-oxo-3-phenylpropyl)octahydro-2H-indol-2-o ne (3ga)

Purification by flash column chromatography (SiO₂, PE/EA = 5:1) afforded 3ga.

White solid, 37.1 mg, 75% yield, mp = 140-142 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.96 (d, J = 7.4 Hz, 2H), 7.54 (t, J = 7.3 Hz, 1H), 7.45–7.39 (m, 4H), 7.32 (d, J = 8.6 Hz, 2H), 4.52 (dd, J = 10.8, 4.8 Hz, 1H), 4.45 (dd, J = 13.0, 7.7 Hz, 1H), 3.14–3.09 (m, 2H), 2.86 (dd, J = 7.1, 5.1 Hz, 1H), 2.20–2.03 (m, 4H), 1.97–1.92 (m, 1H), 1.75–1.72 (m, 1H), 1.61–1.54 (m, 2H), 1.42 (s, 3H), 1.31 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ199.51, 176.68, 148.93, 136.63, 134.40, 132.93, 128.45, 128.07, 125.91, 123.50, 55.67, 50.25, 48.28, 47.75, 34.39, 34.15, 33.63, 31.69, 31.22, 27.13, 20.68, 18.83. HRMS (ESI) for $C_{28}H_{35}BrNO_2$ [M+H]⁺ calcd. 496.1846, found 496.1845.



4-Bromo-1-(4-methoxyphenyl)-3-methyl-3-(3-oxo-3-phenylpropyl)octahydro-2H-indol-2-one (3ha)

Purification by flash column chromatography (SiO₂, PE/EA = 2:1) afforded **3ha**.

Yellow solid, 37.1 mg, 79% yield, mp = 132-134 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.96 (d, *J* = 7.6 Hz, 2H), 7.53 (t, *J* = 7.2 Hz, 1H), 7.43 (t, *J* = 7.4 Hz, 2H), 7.27 (t, *J* = 3.9 Hz, 2H), 6.92 (d, *J* = 7.8 Hz, 2H), 4.57–4.31 (m, 2H), 3.79 (s, 3H),

3.24–3.02 (m, 2H), 2.85 (t, *J* = 5.3 Hz, 1H), 2.12–2.03 (m, 4H), 1.87–1.83 (m, 1H), 1.70–1.67 (m, 1H), 1.60–1.49 (m, 2H), 1.42 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 199.51, 176.81, 157.70, 136.56, 132.93, 129.79, 128.43, 128.02, 125.87, 114.28, 56.09, 55.36, 50.27, 48.55, 47.56, 34.35, 33.57, 31.47, 26.99, 20.41, 18.87. HRMS (ESI) for $C_{25}H_{29}BrNO_3$ [M+H]⁺ calcd. 470.1325, found 470.1326.



4-Bromo-1-(2-methoxyphenyl)-3-methyl-3-(3-oxo-3-phenylpropyl)octahydro-2H-indol-2-one (3ia)

Purification by flash column chromatography (SiO₂, PE/EA = 3:1) afforded **3ia**.

White solid, 32.8 mg, 70% yield, mp = 116-118 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 8.01–7.97 (m, 2H), 7.56–7.52 (m, 1H), 7.44 (t, *J* = 7.6 Hz, 2H), 7.31–7.26 (m, 1H), 7.14 (dd, *J* = 7.7, 1.6 Hz, 1H), 6.99–6.92 (m, 2H), 4.39–4.26 (m, 2H), 3.74 (s, 3H), 3.19–3.13 (m, 2H), 2.78 (t, *J* = 7.0 Hz, 1H), 2.31–2.19 (m, 2H), 2.15–2.05 (m, 1H), 2.03–1.92 (m, 1H), 1.63–1.49 (m, 4H), 1.47 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ199.92, 178.02, 155.19, 136.75, 132.90, 129.89, 129.11, 128.45, 128.02, 125.32, 120.68, 111.86, 56.25, 55.47, 50.61, 50.23, 47.59, 35.78, 33.64, 31.18, 26.50, 19.68, 19.33.

HRMS (ESI) for $C_{25}H_{29}BrNO_3 [M+H]^+$ calcd. 470.1325, found 470.1322.



4-Bromo-1-(3-methoxyphenyl)-3-methyl-3-(3-oxo-3-phenylpropyl)octahydro-2H-indol-2-one (3ja)

Purification by flash column chromatography (SiO₂, PE/EA = 3:1) afforded **3ja**.

White solid, 34.7 mg, 74% yield, mp = 114-116 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.96 (d, *J* = 7.5 Hz, 2H), 7.54 (t, *J* = 7.3 Hz, 1H), 7.45 – 7.41 (m, 2H), 7.31–7.27 (m, 1H), 7.09 (s, 1H), 6.97 (d, *J* = 7.9 Hz, 1H), 6.79–6.76 (m, 1H), 4.54–4.44 (m, 2H), 3.81 (s, 3H), 3.20–3.03 (m, 2H), 2.86 (dd, *J* = 7.0, 5.0 Hz, 1H), 2.21–2.03 (m, 4H), 1.99–1.94 (m 1H), 1.76–1.73 (m, 1H), 1.62–1.50 (m, 2H), 1.42 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 199.30, 176.62, 159.95, 138.21, 136.45, 132.86, 129.54, 128.35, 127.92, 115.61, 111.50, 109.65, 55.52, 55.16, 50.14, 47.97, 47.76, 33.93, 33.47, 31.54, 26.89, 20.58, 18.70.

HRMS (ESI) for $C_{25}H_{29}BrNO_3 [M+H]^+$ calcd. 470.1325, found 470.1326.



4-Bromo-3-methyl-3-(3-oxo-3-phenylpropyl)-1-tosyloctahydro-2H-indol-2-one (3ka)

Purification by flash column chromatography (SiO₂, PE/EA = 3:1) afforded **3ka**.

White solid, 27.4 mg, 53% yield, mp = 102-104 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.95 (d, J = 8.2 Hz, 2H), 7.83 (d, J = 7.6 Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.44 (t, J = 7.7 Hz, 2H), 7.33 (d, J = 8.2 Hz, 2H), 4.68–4.56 (m, 2H), 2.91–2.71 (m, 3H), 2.58–2.50 (m, 1H), 2.40 (s, 3H), 2.13–2.05 (m, 1H), 2.03–1.87 (m, 4H), 1.76–1.73 (m, 1H), 1.54–1.43 (m, 1H), 1.23 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 198.59, 176.35, 145.18, 136.42, 135.79, 133.18, 129.56, 128.54, 128.32, 128.02, 55.54, 48.83, 47.91, 47.28, 33.14, 32.24, 32.02, 29.85, 21.65, 21.58, 18.21. HRMS (ESI) for $C_{25}H_{29}BrNO_4S$ [M+H]⁺ calcd. 518.0995, found 518.0997.



1-Benzyl-4-bromo-3-methyl-3-(3-oxo-3-phenylpropyl)octahydro-2H-indol-2-one (3la) Purification by flash column chromatography (SiO₂, PE/EA = 4:1) afforded **3la**.

White solid, 26.7 mg, 59% yield, mp = 96-98 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 8.01–7.95 (m, 2H), 7.60–7.53 (m, 1H), 7.46 (t, *J* = 7.6 Hz, 2H), 7.37–7.27 (m, 3H), 7.25–7.19 (m, 2H), 4.96 (d, *J* = 15.0 Hz, 1H), 4.44–4.39 (m, 1H), 4.01 (d, *J* = 15.0 Hz, 1H), 3.71–3.66 (m, 1H), 3.17–3.01 (m, 2H), 2.63 (dd, *J* = 7.4, 5.1 Hz, 1H), 2.11–1.97 (m, 4H), 1.96–1.88 (m, 1H), 1.74–1.67 (m, 1H), 1.56–1.44 (m, 2H), 1.35 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ199.53, 177.52, 136.82, 136.65, 133.03, 128.78, 128.58, 128.13, 127.87, 127.64, 53.24, 50.04, 48.58, 46.90, 44.32, 34.11, 33.74, 31.78, 26.92, 20.41, 18.84. HRMS (ESI) for $C_{25}H_{29}BrNO_2$ [M+H]⁺ calcd. 454.1376, found 454.1375.



4-Bromo-3-methyl-3-(3-oxo-3-phenylpropyl)-1-phenylhexahydrocyclopenta[b]pyrrol-2(1H)one (3ma)

Purification by flash column chromatography (SiO₂, PE/EA = 5:1) afforded **3ma**.

White solid, 31.0 mg, 73% yield, mp = 134-136 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 7.95–7.91 (m, 2H), 7.56–7.51 (m, 1H), 7.49–7.36 (m, 6H), 7.22–7.17 (m, 1H), 4.84–4.75 (m, 1H), 4.34 (q, *J* = 5.9 Hz, 1H), 3.15–3.08 (m, 2H), 2.99 (dd, *J* = 7.8, 5.9 Hz, 1H), 2.31–2.14 (m, 2H), 2.09–2.04 (m, 3H), 1.69–1.64 (m, 1H), 1.42 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 199.30, 176.11, 137.35, 136.63, 133.03, 128.93, 128.51, 127.98, 125.43, 122.45, 60.79, 56.89, 50.24, 46.54, 36.36, 34.86, 33.44, 29.93, 17.93.
.HRMS (ESI) for C₂₃H₂₅BrNO₂ [M+H]⁺ calcd. 426.1063, found 426.1074.



4-Bromo-3-(3-(4-chlorophenyl)-3-oxopropyl)-3-methyl-1-phenyloctahydro-2H-indol-2-one (3ab)

Purification by flash column chromatography (SiO₂, PE/EA = 6:1) afforded **3ab**.

White solid, 33.6 mg, 71% yield, mp = 132-134 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 7.89 (d, J = 8.5 Hz, 2H), 7.41–7.38 (m, 6H), 7.25–7.20 (m, 1H), 4.54–4.45 (m, 2H), 3.16–3.01 (m, 2H), 2.86 (dd, J = 7.2, 5.0 Hz, 1H), 2.18–2.04 (m, 4H), 2.00–1.91 (m, 1H), 1.78–1.70 (m, 1H), 1.61–1.51 (m, 2H), 1.42 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 198.35, 176.72, 139.45, 137.12, 134.96, 129.58, 129.11, 128.84, 126.13, 123.98, 55.68, 50.09, 48.40, 47.80, 34.13, 33.65, 31.66, 27.11, 20.75, 18.84.

HRMS (ESI) for C₂₄H₂₆BrClNO₂ [M+H]⁺ calcd. 474.0830, found 474.0844.



4-Bromo-3-(3-(4-bromophenyl)-3-oxopropyl)-3-methyl-1-phenyloctahydro-2H-indol-2-one (3ac)

Purification by flash column chromatography (SiO₂, PE/EA = 3:1) afforded **3ac**.

Yellow solid, 34.6 mg, 67% yield, mp = 116-118 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.82 (d, *J* = 8.3 Hz, 2H), 7.57 (d, *J* = 8.2 Hz, 2H), 7.46–7.35 (m, 4H), 7.29–7.23 (m, 1H), 4.52–4.48 (m, 2H), 3.22–2.98 (m, 2H), 2.95–2.78 (m, 1H), 2.14–2.08 (m, 4H), 1.95–1.91 (m, 1H), 1.76–1.72 (m, 1H), 1.62–1.53 (m, 2H), 1.42 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 198.54, 176.71, 137.10, 135.35, 131.83, 129.69, 129.12, 128.20, 126.14, 123.99, 55.69, 50.08, 48.40, 47.79, 34.13, 33.65 31.64, 27.11, 20.77, 18.84.

HRMS (ESI) for C₂₄H₂₆Br₂NO₂ [M+H]⁺ calcd. 518.0325, found 518.0340.



4-Bromo-3-methyl-3-(3-oxo-3-(p-tolyl)propyl)-1-phenyloctahydro-2H-indol-2-one (3ad) Purification by flash column chromatography (SiO₂, PE/EA = 4:1) afforded **3ad**. Yellow solid, 35.8 mg, 79% yield, mp = 114–116 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 7.86 (d, J = 8.2 Hz, 2H), 7.44–7.35 (m, 4H), 7.24–7.18 (m, 3H), 4.59–4.40 (m, 2H), 3.17–3.01 (m, 2H), 2.86 (dd, J = 7.2, 5.0 Hz, 1H), 2.37 (s, 3H), 2.18–2.03 (m, 4H), 1.97–1.89 (m, 1H), 1.77–1.67 (m, 1H), 1.59–1.49 (m, 2H), 1.41 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 199.11, 176.78, 143.71, 137.17, 134.15, 129.14, 129.01, 128.19, 125.98, 123.92, 55.60, 50.22, 48.24, 47.84, 34.14, 33.47, 31.72, 27.07, 21.52, 20.62, 18.81. HRMS (ESI) for $C_{25}H_{29}BrNO_2$ [M+H]⁺ calcd. 454.1376, found 454.1386.



4-Bromo-3-(3-(4-methoxyphenyl)-3-oxopropyl)-3-methyl-1-phenyloctahydro-2H-indol-2-one (3ae)

Purification by flash column chromatography (SiO₂, PE/EA = 2:1) afforded **3ae**.

White solid, 40.8 mg, 87% yield, mp = 136-138 °C.

¹**H NMR (400 MHz, CDCl₃)** δ7.95 (d, *J* = 8.9 Hz, 2H), 7.43–7.36 (m, 4H), 7.24–7.20 (m, 1H), 6.90 (d, *J* = 8.9 Hz, 2H), 4.54–4.45 (m, 2H), 3.84 (s, 3H), 3.11–2.99 (m, 2H), 2.87 (dd, *J* = 7.2, 4.9 Hz, 1H), 2.17–2.05 (m, 4H), 1.97–1.89 (m, 1H), 1.75–1.69 (m, 1H), 1.59–1.52 (m, 2H), 1.42 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 198.12, 176.86, 163.42, 137.23, 130.42, 129.77, 129.07, 126.05, 124.00, 113.65, 55.67, 55.38, 50.24, 48.27, 47.95, 34.19, 33.32, 31.94, 27.14, 20.69, 18.85. **HRMS (ESI)** for C₂₅H₂₉BrNO₃ [M+H]⁺ calcd. 470.1325, found 470.1338.



3-(3-([1,1'-Biphenyl]-4-yl)-3-oxopropyl)-4-bromo-3-methyl-1-phenyloctahydro-2H-indol-2-o ne (3af)

Purification by flash column chromatography (SiO₂, PE/EA = 3:1) afforded **3af**.

Yellow solid, 39.7 mg, 77% yield, $mp = 78-80^{\circ}C$.

¹**H NMR (400 MHz, CDCl₃)** δ 8.04 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 8.5 Hz, 2H), 7.62–7.60 (m, 2H), 7.47–7.44 (m, 3H), 7.42–7.38 (m, 4H), 7.28–7.21 (m, 1H), 4.58–4.45 (m, 2H), 3.18–3.11 (m, 2H), 2.89 (dd, J = 7.2, 4.9 Hz, 1H), 2.19–2.07 (m, 4H), 1.98–1.91 (m, 1H), 1.77–1.70 (m, 1H), 1.62–1.53 (m, 2H), 1.44 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ¹³C NMR (101 MHz, CDCl₃) δ 199.18, 176.85, 145.70, 139.89, 137.25, 135.42, 129.11, 128.89, 128.76, 128.14, 127.23, 127.19, 126.10, 124.04, 55.73, 50.20, 48.41, 47.94, 34.22, 33.75, 31.83, 27.17, 20.74, 18.89.

HRMS (**ESI**) for C₃₀H₃₁BrNO₂ [M+H]⁺ calcd. 516.1533, found 516.1548.



4-Bromo-3-(3-(2-fluorophenyl)-3-oxopropyl)-3-methyl-1-phenyloctahydro-2H-indol-2-one (3ag)

Purification by flash column chromatography (SiO₂, PE/EA = 3:1) afforded **3ag**. White solid, 32.0 mg, 70% yield, mp = 144-146 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 7.81 (t, J = 7.1 Hz, 1H), 7.50–7.46 (m, 1H), 7.42–7.36 (m, 4H), 7.23–7.17 (m, 2H), 7.12–7.07 (m, 1H), 4.50–4.45 (m, 2H), 3.24–3.14 (m, 1H), 3.11–3.01 (m, 1H), 2.90–2.82 (m, 1H), 2.20–2.03 (m, 4H), 1.95–1.91 (m, 1H), 1.73–1.69 (m, 1H), 1.61–1.50 (m, 2H), 1.42 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 197.72 (d, J = 4.0 Hz), 176.74, 161.68 (d, J = 256.5 Hz), 137.16, 134.35 (d, J = 9.0 Hz), 130.52, 128.95, 125.94, 125.54 (d, J = 12.9 Hz), 124.31, 123.99, 116.66, 116.43, 55.61, 50.32, 48.33, 47.63, 38.45, 34.21, 31.34, 27.04, 20.44, 18.82.

HRMS (ESI) for $C_{24}H_{26}BrFNO_2 [M+H]^+$ calcd. 458.1125, found 458.1137.



4-Bromo-3-(3-(2-hydroxyphenyl)-3-oxopropyl)-3-methyl-1-phenyloctahydro-2H-indol-2-one (3ah)

Purification by flash column chromatography (SiO₂, PE/EA = 2:1) afforded **3ah**.

Yellow solid, 25.9 mg, 57% yield, mp = 128-130 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 12.22 (s, 1H), 7.79 (d, J = 7.7 Hz, 1H), 7.46–7.38 (m, 5H), 7.24–7.21 (m, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.87 (t, J = 7.5 Hz, 1H), 4.57–4.45 (m, 2H), 3.23–3.08 (m, 2H), 2.87 (dd, J = 7.1, 4.8 Hz, 1H), 2.17–2.06 (m, 4H), 1.98–1.94 (m, 1H), 1.76–1.70 (m, 1H), 1.61–1.53 (m, 2H), 1.43 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 205.73, 176.58, 162.34, 137.10, 136.34, 130.12, 129.12, 126.14, 123.93, 119.11, 118.98, 118.38, 55.68, 49.94, 48.27, 47.80, 34.02, 33.44, 31.65, 27.11, 20.80, 18.80.

HRMS (ESI) for C₂₄H₂₇BrNO₃ [M+H]⁺ calcd. 456.1169, found 456.1179.



4-Bromo-3-(3-(2-methoxyphenyl)-3-oxopropyl)-3-methyl-1-phenyloctahydro-2H-indol-2-one (3ai)

Purification by flash column chromatography (SiO₂, PE/EA = 3:1) afforded **3ai**. Yellow oil, 38.9 mg, 83% yield.

¹**H NMR (400 MHz, CDCl₃)** δ 7.65 (dd, *J* = 7.7, 1.8 Hz, 1H), 7.45–7.35 (m, 5H), 7.23–7.20 (m, 1H), 7.00–6.92 (m, 2H), 4.53–4.43 (m, 2H), 3.87 (s, 3H), 3.15–3.08 (m, 2H), 2.85 (dd, *J* = 7.0, 5.2 Hz, 1H), 2.16–2.02 (m, 4H), 1.93–1.89 (m, 1H), 1.75–1.67 (m, 1H), 1.61–1.55 (m, 2H), 1.40 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 201.86, 177.08, 158.40, 137.35, 133.32, 130.27, 129.01, 128.25, 125.94, 124.01, 120.58, 111.48, 55.66, 55.53, 50.73, 48.30, 47.96, 38.79, 34.44, 31.84, 27.19, 20.34, 18.94.

HRMS (ESI) for $C_{25}H_{29}BrNO_3 [M+H]^+$ calcd. 470.1325, found 470.1339.



4-Bromo-3-(3-(3-chlorophenyl)-3-oxopropyl)-3-methyl-1-phenyloctahydro-2H-indol-2-one (3aj)

Purification by flash column chromatography (SiO₂, PE/EA = 4:1) afforded **3aj**.

Yellow solid, 35.5 mg, 75% yield, mp = 116-118 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.92 (t, *J* = 1.8 Hz, 1H), 7.83 (d, *J* = 7.8 Hz, 1H), 7.53–7.49 (m, 1H), 7.43–7.35 (m, 5H), 7.25–7.21 (m, 1H), 4.55–4.46 (m, 2H), 3.18–3.02 (m, 2H), 2.85 (dd, *J* = 7.2, 5.0 Hz, 1H), 2.16–2.08 (m, 4H), 1.97–1.90 (m, 1H), 1.78–1.70 (m, 1H), 1.62–1.53 (m, 2H), 1.43 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 198.18, 176.69, 138.19, 137.08, 134.83, 132.92, 129.86, 129.07, 128.08, 126.24, 124.09, 123.96, 55.66, 50.07, 48.46, 47.71, 34.14, 33.72, 31.46, 27.03, 20.67, 18.83.

HRMS (ESI) for $C_{24}H_{26}BrClNO_2 [M+H]^+$ calcd. 474.0830, found 474.0842.



4-Bromo-3-(3-(3,4-dimethoxyphenyl)-3-oxopropyl)-3-methyl-1-phenyloctahydro-2H-indol-2one (3ak)

Purification by flash column chromatography (SiO₂, PE/EA = 2:1) afforded **3ak**.

White solid, 39.9 mg, 80% yield, mp = 144-146 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.61 (dd, J = 8.4, 1.9 Hz, 1H), 7.52 (d, J = 1.9 Hz, 1H), 7.44–7.37 (m, 4H), 7.25–7.20 (m, 1H), 6.86 (d, J = 8.4 Hz, 1H), 4.55–4.45 (m, 2H), 3.92 (s, 3H), 3.91 (s, 3H), 3.13–3.00 (m, 2H), 2.88 (dd, J = 7.2, 4.9 Hz, 1H), 2.14–2.08 (m, 4H), 1.99–1.92 (m, 1H), 1.75–1.71 (m, 1H), 1.61–1.52 (m, 2H), 1.42 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 198.28, 176.83, 153.20, 148.92, 137.21, 129.85, 129.07, 126.05, 123.94, 122.94, 110.19, 109.97, 55.99, 55.95, 55.64, 50.24, 48.18, 47.98, 34.12, 33.27, 32.17, 27.16, 20.74, 18.82.

HRMS (ESI) for $C_{26}H_{31}BrNO_4 [M+H]^+$ calcd. 500.1431, found 500.1446.



4-Bromo-3-methyl-3-(3-(naphthalen-2-yl)-3-oxopropyl)-1-phenyloctahydro-2H-indol-2-one (3al)

Purification by flash column chromatography (SiO₂, PE/EA = 6:1) afforded **3al**.

White solid, 38.1 mg, 78% yield, mp = 140-142 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 8.49 (s, 1H), 8.03 (dd, J = 8.6, 1.7 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.89–7.83 (m, 2H), 7.60–7.51 (m, 2H), 7.45–7.38 (m, 4H), 7.25–7.19 (m, 1H), 4.57–4.48 (m, 2H), 3.32–3.19 (m, 2H), 2.90 (dd, J = 7.2, 4.9 Hz, 1H), 2.22–2.17 (m, 2H), 2.14–2.07 (m, 2H), 1.98–1.90 (m, 1H), 1.77–1.70 (m, 1H), 1.63–1.52 (m, 2H), 1.46 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 199.48, 176.86, 137.18, 135.53, 133.97, 132.46, 129.83, 129.60, 129.10, 128.35, 127.66, 126.65, 126.08, 123.98, 123.86, 55.66, 50.24, 48.40, 47.93, 34.20, 33.69, 31.78, 27.13, 20.74, 18.86.

HRMS (**ESI**) for C₂₈H₂₉BrNO₂ [M+H]⁺ calcd. 490.1376, found 490.1386.



4-Bromo-3-(3-cyclopropyl-3-oxopropyl)-3-methyl-1-phenyloctahydro-2H-indol-2-one (3am) Purification by flash column chromatography (SiO₂, PE/EA = 8:1) afforded **3am**. White solid, 28.2 mg, 70% yield, mp = 70–72 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.41–7.36 (m, 4H), 7.24–7.20 (m, 1H), 4.50–4.42 (m, 2H), 2.81–2.63 (m, 3H), 2.15–2.02 (m, 2H), 2.00–1.89 (m, 4H), 1.76–1.68 (m, 1H), 1.61–1.50 (m, 2H), 1.37 (s, 3H), 1.02–0.97 (m, 2H), 0.86–0.83 (m, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 209.95, 176.80, 137.21, 129.02, 126.01, 123.95, 55.63, 50.28, 48.21, 47.76, 38.35, 34.24, 31.13, 27.07, 20.57, 20.53, 18.88, 10.78, 10.74.

HRMS (ESI) for C₂₁H₂₇BrNO₂ [M+H]⁺ calcd. 404.1220, found 404.1229.



4-Chloro-3-methyl-3-(3-oxo-3-phenylpropyl)-1-phenyloctahydro-2H-indol-2-one (3an)

Purification by flash column chromatography (SiO₂, PE/EA = 6:1) afforded **3an**.

White solid, 26.1 mg, 66% yield, mp = 140-142 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 7.98–7.94 (m, 2H), 7.54 (t, J = 7.4 Hz, 1H), 7.46–7.40 (m, 3H), 7.39–7.34 (m, 3H), 7.26–7.21 (m, 1H), 4.49 (dd, J = 12.4, 6.8 Hz, 1H), 4.31–4.26 (m, 1H), 3.21–3.06 (m, 2H), 2.63 (t, J = 6.5 Hz, 1H), 2.16–2.08 (m, 3H), 1.92–1.80 (m, 2H), 1.70–1.63 (m, 2H), 1.49–1.44 (m, 1H), 1.43 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 199.57, 177.06, 137.06, 136.66, 132.99, 129.02, 128.49, 128.05, 126.14, 124.32, 57.67, 55.61, 48.61, 47.51, 33.86, 33.57, 31.27, 26.54, 20.10, 18.11.

HRMS (ESI) for $C_{24}H_{27}CINO_2 [M+H]^+$ calcd. 396.1725, found 396.1735.



4-Bromo-3-(3-(4-methoxyphenyl)-3-oxopropyl)-3-methyl-1-tosyloctahydro-2H-indol-2-one (3ke)

Purification by flash column chromatography (SiO₂, PE/EA = 3:1) afforded **3ke**.

White solid, 34.5 mg, 63% yield, mp = 134-136 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.96 (d, *J* = 8.3 Hz, 2H), 7.82 (d, *J* = 8.9 Hz, 2H), 7.34 (d, *J* = 8.2 Hz, 2H), 6.91 (d, *J* = 8.9 Hz, 2H), 4.67–4.58 (m, 2H), 3.88 (s, 3H), 2.84–2.69 (m, 3H), 2.58–2.52 (m, 1H), 2.42 (s, 3H), 2.11–2.06 (m, 1H), 2.01–1.87 (m, 4H), 1.79–1.71 (m, 1H), 1.53–1.44 (m, 1H), 1.22 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 197.18, 176.42, 163.46, 145.20, 135.64, 130.31, 129.57, 129.37, 128.27, 113.61, 55.46, 48.97, 47.95, 47.05, 32.75, 32.32, 31.92, 29.88, 21.71, 21.65, 18.14. HRMS (ESI) for $C_{26}H_{31}BrNO_5S$ [M+H]⁺ calcd. 548.1101, found 548.1095.



1-Benzyl-4-bromo-3-(3-(4-methoxyphenyl)-3-oxopropyl)-3-methyloctahydro-2H-indol-2-one (3le)

Purification by flash column chromatography (SiO₂, PE/EA = 2:1) afforded **3le**.

White solid, 26.6 mg, 55% yield, mp = 86-88 °C.

¹**H NMR (400 MHz, CDCl₃)** δ 7.97 (d, *J* = 8.8 Hz, 2H), 7.34–7.29 (m, 3H), 7.22 (d, *J* = 6.6 Hz, 2H), 6.94 (d, *J* = 8.8 Hz, 2H), 4.97 (d, *J* = 15.0 Hz, 1H), 4.43–4.41 (m, 1H), 4.00 (d, *J* = 15.0 Hz, 1H), 3.88 (s, 3H), 3.71–3.66 (m, 1H), 3.15–2.93 (m, 2H), 2.67–2.59 (m, 1H), 2.06–2.02 (m, 4H), 1.93–1.86 (m, 1H), 1.72–1.61 (m, 1H), 1.54–1.45 (m, 2H), 1.35 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 198.14, 177.52, 163.39, 136.55, 130.41, 129.75, 128.76, 127.82, 127.61, 113.66, 55.44, 53.07, 50.17, 48.31, 46.95, 44.21, 34.05, 33.37, 31.86, 26.93, 20.44, 18.78. HRMS (ESI) for $C_{26}H_{31}BrNO_3$ [M+H]⁺ calcd. 484.1482, found 484.1479.



3-Methyl-3-(3-oxo-3-phenylpropyl)-1-phenyl-1,3,3a,6,7,7a-hexahydro-2H-indol-2-one (4aa) Purification by flash column chromatography (SiO₂, PE/EA = 4:1) afforded **4aa**. White solid, 33.4 mg, 93% yield, mp = 103-105 °C.

¹**H** NMR (400 MHz, CDCl₃) δ 8.01–7.92 (m, 2H), 7.53 (t, J = 7.4 Hz, 1H), 7.49–7.35 (m, 6H), 7.21 (t, J = 7.2 Hz, 1H), 6.03–5.89 (m, 1H), 5.74–5.60 (m, 1H), 4.43 (td, J = 8.5, 3.8 Hz, 1H), 3.20–3.13 (m, 2H), 2.90–2.79 (m, 1H), 2.21–2.03 (m, 2H), 1.99–1.85 (m, 3H), 1.71–1.64 (m, 1H), 1.26 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 200.11, 177.56, 137.47, 136.68, 133.01, 128.96, 128.52, 128.14, 125.71, 124.22, 123.77, 55.60, 47.07, 40.47, 33.83, 32.34, 24.76, 21.28, 20.91.

HRMS (ESI) for $C_{24}H_{26}NO_2 [M+H]^+$ calcd. 360.1958, found 360.1955.

6. X-Ray crystallographic data

6.1 X-Ray Crystallographic Data of Product 3aa

The crystal structure **3aa** has been deposited at the Cambridge Crystallographic Data Centre and allocated the deposition number: **CCDC 1950969**.



6.2 X-Ray Crystallographic Data of product 3an

The crystal structure **3an** has been deposited at the Cambridge Crystallographic Data Centre and allocated the deposition number: **CCDC 1950971**.





Bond precision:	C-C =0.0028 A		Waveleng	th=1.54184
Cell:	a=8.7322(5)	b=9.3453(4)		c=13.9189(7)
	alpha=90.640(4)	beta=99.884	(4)	gamma=116.102(5)
Temperature:	292 K			
	Calculated		Reported	
Volume	1000.03(10)		1000.04(9)
Space group	P -1		P -1	
Hall group	-P 1		-P 1	
Moiety formula	C24 H26 Cl N O2		C24 H26 0	Cl N O2
Sum formula	C24 H26 Cl N O2		C24 H26 0	Cl N O2
Mr	395.91		395.91	
Dx,g cm-3	1.315		1.315	
Z	2		2	
Mu (mm-1)	1.839		1.839	
F000	420.0		420.0	
F000'	421.81			
h,k,lmax	10,11,16		10,11,16	
Nref	3537		3537	
Tmin,Tmax	0.740,0.802		0.740,0.80	02
Tmin'	0.672			
Correction method= # Reported T Limits: Tmin=0.248 Tmax=1.000				
AbsCorr = MULTI-SCAN				
Data completeness=0.999		Theta(max)= 66	5.595	
R(reflections)= 0.0473(3266	6)	wR2(reflections	s)= 0.1248((3532)
S =1.078		Npar=261		

7. Mechanistic studies

7.1 Radical trapping experiments



The radical trapping experiments were conducted with different scavengers to capture the radical intermediates in the system, and the products were detected by HRMS. Under the standard conditions, TEMPO-trapped product **5** and **6** were observed when TEMPO was used as the scavenger with no product **3aa** detected (Scheme 4a). This observation indicated the existence of radical intermediates II and IV. Moreover, both product **3aa** and **7** were observed when H_2O was added to the reaction (Scheme 4b). This observation indicated the existence of carbon cation intermediate **V**.



HRMS (ESI) for $C_{17}H_{26}NO_2 [M+H]^+$ calcd. 276.1958, found 276.1960.



HRMS (ESI) for $C_{33}H_{44}N_2NaO_3 [M+H]^+$ calcd. 539.3244, found 539.3245.



HRMS (ESI) for $C_{24}H_{28}NO_3 [M+H]^+$ calcd. 378.2064, found 378.2064.

7.2 Stern-Volmer fluorescence quenching experiments

According to the procedure of related literature, Stern-Volmer fluorescence quenching experiments were run with freshly prepared solutions of 0.1 mM *fac*-Ir(ppy)₃ in toluene at room temperature. The solutions were irradiated at 375 nm and fluorescence was measured from 450 nm to 650 nm. Control experiments show that excited state of *fac*-Ir(ppy)₃ was primarily quenched by 2-bromoacetophenone **2a** while 1,6-dienes **1a** and 2,6-lutidine showed a much less effect.



Fig. S1. Fluorescence quenching date with fac-Ir(ppy)₃ and variable 1,6-dienes 1a.



Fig. S2. Fluorescence quenching date with fac-Ir(ppy)₃ and variable 2-bromoacetophenone 2a.



Figure S3. Fluorescence quenching experiments date with *fac*-Ir(ppy)₃ and variable 2, 6-lutidine.



Figure S4. Stern-Volmer plots of *fac*-Ir(ppy)₃ with different quenchers.

8. NMR spectra of products





¹H NMR of **3ba** in CDCl₃



S29

¹H NMR of **3ca** in CDCl₃



¹H NMR of **3da** in CDCl₃

777 368 778 368 779 368 779 369 779 369 779 369 779 369 779 369 771 450 771 450 771 450 771 450 771 450 771 450 771 450 771 450



¹³C NMR of **3da** in CDCl₃



¹H NMR of **3ea** in CDCl₃



¹³C NMR of **3ea** in CDCl₃



¹H NMR of **3fa** in CDCl₃



¹³C NMR of **3fa** in CDCl₃





¹H NMR of **3ga** in CDCl₃



¹³C NMR of **3ga** in CDCl₃



¹H NMR of **3ha** in CDCl₃



S35

¹H NMR of **3ia** in CDCl₃



¹³C NMR of **3ia** in CDCl₃





¹H NMR of **3ja** in CDCl₃





¹H NMR of **3la** in CDCl₃



¹H NMR of **3ma** in CDCl₃



¹³C NMR of **3ma** in CDCl₃





¹H NMR of **3ab** in CDCl₃



¹³C NMR of **3ab** in CDCl₃



¹H NMR of **3ac** in CDCl₃



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)

¹H NMR of **3ad** in CDCl₃



¹³C NMR of **3ad** in CDCl₃



¹H NMR of **3ae** in CDCl₃





210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)

¹H NMR of **3af** in CDCl₃

8 046 8



¹³C NMR of **3af** in CDCl₃



¹H NMR of **3ag** in CDCl₃



¹³C NMR of **3ag** in CDCl₃



¹H NMR of **3ah** in CDCl₃



¹³C NMR of **3ah** in CDCl₃



¹H NMR of **3ai** in CDCl₃



¹³C NMR of **3ai** in CDCl₃



¹H NMR of **3aj** in $CDCl_3$



¹³C NMR of **3aj** in CDCl₃



 1 H NMR of **3ak** in CDCl₃



¹³C NMR of **3ak** in CDCl₃

-196.278 -176.826 -176.826 -135.201 -135.201 -132.2016 7.122.841 7.122.841 7.122.841 7.122.841 7.122.841 7.122.841	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} $
---	--



¹H NMR of **3al** in CDCl₃



¹³C NMR of **3al** in CDCl₃





¹³C NMR of **3am** in CDCl₃



¹H NMR of **3an** in CDCl₃

77,7585 77,75857 77,75857 75,5587 77,5587 77,5587 77,5587 77,5587 77,5587 77,7587 77,7587 77,7388 77,7388 77,7387 74,4287 7



¹³C NMR of **3an** in CDCl₃





¹H NMR of **3ke** in CDCl₃



¹H NMR of **3le** in CDCl₃



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)

¹H NMR of **4aa** in CDCl₃

77, 287 77, 287 77, 287 77, 287 77, 287 77, 287 77, 287 77, 287 77, 287 77, 287 77, 287 77, 287 77, 288 76, 288 76,



¹³C NMR of **4aa** in CDCl₃



